Sandoz to buy eye drug Cimerli in $170 million deal

ZURICH (Reuters) - Sandoz on Monday announced a deal to buy Cimerli, a biosimilar drug to treat vision impairment and loss, from Coherus BioSciences Inc. for $170 million.

The drug is interchangeable with Lucentis, a product marketed by Roche's Genentech in the United States and by Novartis in the rest of the world, for all approved indications, Sandoz said.

(Reporting by John Revill, Editing by Linda Pasquini)